Trial · NCT06887621
Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery
NCT06887621, Phase 2, Active not recruiting, Instituto do Cancer do Estado de São Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery. Trials, record NCT06887621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06887621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery
- NCT number
- NCT06887621
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 276 participants, estimated
- Lead sponsor
- Instituto do Cancer do Estado de São Paulo
- Conditions
- Post Operative Nausea and Vomiting (PONV)
- Interventions
- Encapsulated amisulpride 50 mg (matched for color, weight, smell and size), Encapsulated placebo (matched for color, weight, smell and size)
- First posted
- 2025-03-20
- Last updated
- 2026-09-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with complete response | 24 hours after the end of anesthesia | Complete response defined as the absence of emetic episodes (nausea, vomiting or retching) and no use of antiemetic medications. |
| Secondary | Time to first violation of the criteria for complete response | 24 hours after the end of anesthesia | Time in minutes from the end of anesthesia until violation of criteria for complete response, defined as the absence of emetic episodes (nausea, vomiting or retching) and no use of antiemetic medications. |
| Secondary | Number of participants with any nausea | 24 hours after the end of anesthesia | Nausea (defined as unpleasant, subjective abdominal discomfort associated with the desire to vomit) measured on a 0 to 10 verbal response scale, in which 0 = no nausea at all and 10 = the worst nausea imaginable. "Any nausea" means a score ≥ 1. |
| Secondary | Number of participants with vomiting | 24 hours after the end of anesthesia | Any vomiting (expulsion of gastric contents) or dry-retching. |
| Secondary | Number of participants with nausea and vomiting | 24 hours after the end of anesthesia | Any nausea, vomiting, or dry-retching. |
| Secondary | Nausea Intensity | 24 hours after the end of anesthesia | 0 to 10 scale |
| Secondary | Number of Participants Receiving Rescue Medication | 24 hours after the end of anesthesia | Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or vomiting and/or dry-retching, or any incidental use of a drug known to have antiemetic potential |
| Secondary | Total number of adverse events | 48 hours after ingestion of the capsule | Any adverse event |
| Secondary | Number of serious adverse event | 48 hours after ingestion of the capsule | Any adverse event classified as severe or life-threatening |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06887621
GET https://conductscience.org/api/trials/v1/NCT06887621/registered